Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone (2016)
- Authors:
- Autor USP: RONSEIN, GRAZIELLA ELIZA - IQ
- Unidade: IQ
- DOI: 10.1074/mcp.M115.054528
- Subjects: APOLIPOPROTEÍNAS; LIPOPROTEÍNAS HDL; DIABETES MELLITUS
- Language: Inglês
- Imprenta:
- Source:
- Título: Molecular e Cellular Proteomics
- ISSN: 1535-9476
- Volume/Número/Paginação/Ano: v. 15, n. 3, p. 1083-1093, 2016
- Status:
- Artigo aberto em periódico híbrido (Hybrid Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
RONSEIN, Graziella Eliza et al. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, v. 15, n. 3, p. 1083-1093, 2016Tradução . . Disponível em: https://doi.org/10.1074/mcp.M115.054528. Acesso em: 31 mar. 2026. -
APA
Ronsein, G. E., Reyes Soffer, G., He, Y., Oda, M., Ginsberg, H., & Heinecke, J. W. (2016). Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, 15( 3), 1083-1093. doi:10.1074/mcp.M115.054528 -
NLM
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1074/mcp.M115.054528 -
Vancouver
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1074/mcp.M115.054528 - Investigating the relationship between High-Density Lipoprotein (HDL) and endothelial cells
- HDL proteome: from its characterization to quantitative measurements in particle subspecies and functional associations
- Cholesterol efflux capacity and subclasses of HDL particles in healthy women transitioning through menopause
- Plasminogen promotes cholesterol efflux by the ABCA1 pathway
- Time to ditch HOL-C as a measure of PINION HOL function?
- Inflammation, remodeling, and other factors affecting HDL cholesterol efflux
- Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects
- Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway
- Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced HDL particle concentration
- Diabetes impairs cellular cholesterol efflux from ABCA1 to small HDL particles
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
